Clinical Trials on Keratitis in Switzerland

Total 110 results

GlaxoSmithKline

Completed

Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y

Hepatitis B

Australia, Czech Republic, Germany, Italy, Netherlands, Switzerland, United Kingdom
Allerderm

Completed

Clinical Evaluation of Metal Panel Allergens: Dose Response Study

Dermatitis, Eczematous

Japan, United States, Germany, Italy, Netherlands, Switzerland
University Hospital Inselspital, Berne

Completed

TAF for HIV-HBV With Renal Dysfunction

HIV and Hepatitis B Coinfection

Switzerland
Spirig Pharma Ltd.

Terminated

Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients

Actinic Keratoses | Squamous Cell Carcinomas

Ireland, Austria, Netherlands, United Kingdom, Czech Republic, France, Germany, Switzerland, Turkey
Janssen Pharmaceutica N.V., Belgium

Completed

Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C (INTEGRATE)

Hepatitis, Chronic

France, United Kingdom, Belgium, Germany, Netherlands, Switzerland
Welcare Industries SpA
Oncology Institute of Southern Switzerland

Withdrawn

Jalosome® Soothing Gel Efficacy Grade 2 or 3 Radiodermatitis.

Quality of Life | Pain | Radiodermatitis | Oncology

Switzerland
Boehringer Ingelheim

Completed

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Hepatitis C, Chronic

France, Germany, Switzerland
Kirby Institute
Merck Sharp & Dohme LLC

Completed

A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3 (ACTIVATE)

Hepatitis C, Chronic

Australia, Canada, United Kingdom, Belgium, Germany, Norway, Switzerland
Clinuvel Pharmaceuticals Limited

Unknown

Phase II AK Study in Organ Transplant Patients

Carcinoma, Squamous Cell | Actinic Keratoses | Organ Transplant Recipients

Australia, Sweden, Switzerland, Italy, France, Belgium, Germany
Kirby Institute

Completed

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients (SMART-C)

Hepatitis C, Chronic

United States, United Kingdom, Australia, France, New Zealand, Canada, Switzerland, Germany
Novartis Pharmaceuticals

Active, not recruiting

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade (AMBER)

Autoimmune Hepatitis

United States, Belgium, Germany, United Kingdom, Spain, Switzerland, Argentina, Canada, Japan, Czechia
University of Zurich

Unknown

Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases (NEUTROGENE)

Pustular Psoriasis | Erosive Pustular Dermatosis of the Scalp | Behcet's Disease | Dermatitis Herpetiformis | Pyoderma Gangrenosum | Linear IgA Bullous Dermatosis | Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue | Sweet's Syndrome | Bowel-associated Dermatosis-arthritis Syndrome | Acute Generalized Exanthematous Pustulosis and other conditions

Switzerland
Boehringer Ingelheim

Completed

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

Hepatitis C, Chronic

United States, Australia, Austria, France, Germany, New Zealand, Portugal, Romania, Spain, Switzerland
Hoffmann-La Roche

Completed

Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Chronic Hepatitis B

China, Korea, Republic of, Taiwan, Germany, United States, Singapore, Switzerland, Canada, Puerto Rico, Thailand, Israel, France, New Zealand, Poland, United Kingdom, Brazil, Australia
Gilead Sciences

Completed

Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)

Alcoholic Hepatitis (AH)

Austria, United Kingdom, France, United States, Canada, Belgium, Switzerland
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Hepatitis C, Chronic

United States, Australia, United Kingdom, Germany, France, Spain, Belgium, Netherlands, Canada, Brazil, Puerto Rico, Poland, Sweden, Switzerland, Israel
AbbVie

Completed

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (MAGELLAN-3)

Hepatitis C Virus Infection

United States, Australia, Canada, China, Germany, Korea, Republic of, New Zealand, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Boehringer Ingelheim

Completed

Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

Hepatitis C, Chronic

United States, Brazil, France, Germany, Italy, Spain, Switzerland, United Kingdom
Eiger BioPharmaceuticals

Completed

Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a (D-LIVR)

Hepatitis Delta Virus

United States, Belgium, Spain, Greece, Canada, Italy, Romania, Germany, Israel, Bulgaria, Taiwan, Turkey, Pakistan, Sweden, Ukraine, New Zealand, Russian Federation, United Kingdom, Moldova, Republic of, France, Mongolia, Switzerland
Bristol-Myers Squibb

Completed

Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection (COMMAND-3)

Hepatitis C

Australia, France, Germany, Italy, United Kingdom, United States, Canada, Poland, Austria, Denmark, Israel, Spain, Russian Federation, Switzerland, Argentina, Brazil
Janssen-Cilag International NV

No longer available

Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C

Australia, Belgium, Germany, Spain, Switzerland, Romania, Serbia, Greece, New Zealand, Brazil, Russian Federation, Austria, Hungary, Czech Republic, Luxembourg
Tibotec BVBA
Tibotec Pharmaceutical Limited

Completed

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Hepatitis C, Chronic

United States, Australia, France, United Kingdom, Germany, Spain, Belgium, Israel, Canada, Brazil, Austria, Poland, Netherlands, Sweden, Switzerland, Puerto Rico
Hoffmann-La Roche

Completed

REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy

Hepatitis C, Chronic

Belgium, France, Germany, Italy, Spain, Sweden, United States, Greece, Portugal, Turkey, Switzerland, Canada, United Kingdom, Brazil
Hoffmann-La Roche

Completed

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Hepatitis C, Chronic

Belgium, United States, Germany, Canada, Austria, Switzerland, Puerto Rico, Australia, Brazil, Mexico
Pfizer

Terminated

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

Atopic Dermatitis

United States, Poland, Germany, United Kingdom, Italy, Sweden, Switzerland
AbbVie

Completed

Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6

Hepatitis C

Austria, Belgium, France, Greece, Israel, Italy, Poland, Portugal, Switzerland
Novartis Pharmaceuticals

Completed

Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C (SUSTAIN)

Liver Transplantation | Hepatitis C

Spain, Germany, Switzerland, Italy, United States, Korea, Republic of, Canada, Colombia, Belgium, Brazil, France, United Kingdom, Russian Federation
Kirby Institute

Completed

Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection. (REACT)

Hepatitis C

Australia, United States, United Kingdom, New Zealand, Switzerland, Canada, Germany, Netherlands
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Chronic HCV Infection

Belgium, Austria, New Zealand, United Kingdom, Germany, Spain, Netherlands, France, Switzerland, Canada, Australia, Italy
Galderma R&D

Completed

A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis

Prurigo Nodularis

United States, Austria, France, Germany, Poland, Korea, Republic of, Switzerland
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Hepatitis C, Chronic

United States, Austria, Belgium, Canada, France, Germany, Japan, Portugal, Puerto Rico, Spain, Switzerland, United Kingdom
Astellas Pharma Inc

Completed

Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment

Dermatitis, Atopic

France, Germany, Spain, Belgium, Netherlands, Finland, Austria, United Kingdom, Italy, Czech Republic, Switzerland, Portugal, Denmark
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
Hoffmann-La Roche

Completed

A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Belgium, France, Germany, Sweden, Switzerland, Turkey, Greece, Taiwan, Estonia, Slovakia, Italy, Romania, Lithuania, Serbia, Portugal, Egypt, Pakistan, Mexico, Peru, Lebanon, United States, Argentina, Chile, Kuwait, Latvia, Macedonia, The... and more
Boehringer Ingelheim

Completed

Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

Hepatitis C, Chronic

United States, Argentina, Australia, Austria, Canada, Czech Republic, France, Germany, Korea, Republic of, Netherlands, Portugal, Romania, Spain, Switzerland, United Kingdom
Bristol-Myers Squibb

Completed

Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir (PEDESTAL)

Hepatitis C Virus

Belgium, Germany, Spain, United States, Canada, Brazil, Austria, France, Israel, Switzerland, Italy, Russian Federation, Czechia, Poland, United Kingdom
Bristol-Myers Squibb

Completed

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) (Hallmark QUAD)

Hepatitis C Virus

United States, Germany, Italy, Korea, Republic of, Sweden, Russian Federation, Canada, France, Argentina, Switzerland, Denmark, Taiwan, Netherlands, Spain, Mexico
Hoffmann-La Roche

Completed

An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Belgium, France, Germany, Sweden, Switzerland, Turkey, Greece, Ireland, Taiwan, Estonia, Hungary, Italy, Romania, United Kingdom, Serbia, Morocco, Portugal, Saudi Arabia, Egypt, Pakistan, Lebanon, Macedonia, The Former Yugoslav Republic... and more
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)

Hepatitis C

Austria, Belgium, France, Germany, Japan, Portugal, Romania, Russian Federation, Spain, Switzerland, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"

Atopic Dermatitis

France, United States, Australia, Germany, Israel, Italy, Spain, Switzerland, United Arab Emirates, United Kingdom
Boehringer Ingelheim

Completed

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

Hepatitis C

United States, Austria, Belgium, Canada, France, Germany, Japan, Korea, Republic of, Portugal, Romania, Russian Federation, Spain, Switzerland, Taiwan, United Kingdom
Pfizer

Available

Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

Taiwan, United States, Australia, Austria, Belgium, Canada, Greece, Mexico, Netherlands, Russian Federation, Spain, Switzerland
Hoffmann-La Roche

Completed

A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Korea, Republic of, Canada, United Kingdom, Germany, Australia, Poland, Finland, France, Spain, Switzerland, Czechia, Netherlands, Taiwan
Janssen R&D Ireland

Completed

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy (ATTAIN)

Hepatitis C

United States, Australia, France, Poland, United Kingdom, Germany, Spain, Belgium, Israel, Portugal, Bulgaria, Romania, Denmark, Greece, Sweden, Canada, Czech Republic, Argentina, Brazil, Austria, Hungary, Switzerland, Puerto Rico, No...
Eli Lilly and Company
Incyte Corporation

Completed

Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis (BREEZE-AD2)

Atopic Dermatitis

Spain, Australia, Switzerland, Israel, Korea, Republic of, Japan, Poland, Argentina, Austria, Hungary
Swiss Group for Clinical Cancer Research

Completed

F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer

Breast Cancer | Palmar-plantar Erythrodysesthesia

Switzerland
Amgen
AstraZeneca

Terminated

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

Atopic Dermatitis

United Kingdom, Spain, Australia, Hungary, Switzerland, United States, Germany, Korea, Republic of, Canada, Czechia, Poland, Japan, Estonia, Latvia, Ukraine
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis (TRuE-AD4)

Atopic Dermatitis

Germany, Poland, United States, Spain, United Kingdom, Italy, Belgium, Canada, Netherlands, Australia, Bulgaria, France, Switzerland, Hungary, Korea, Republic of
Eli Lilly and Company
Incyte Corporation

Completed

A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable (BREEZE-AD4)

Atopic Dermatitis

Belgium, Netherlands, Japan, Spain, Switzerland, United Kingdom, Germany, France, Austria, Russian Federation, Poland, Italy, Brazil, Finland
AbbVie

Recruiting

A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis (AD-VISE)

Atopic Dermatitis

Australia, Austria, Canada, Spain, Switzerland, Taiwan, United Arab Emirates, Poland, Czechia, Greece, Russian Federation, Italy, Israel, Argentina, Hungary, Mexico

Clinical Trials on Keratitis in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations